Dynavax Technologies Corp.

NASDAQ:DVAX  
4.77
+0.52 (+12.24%)
Products, Regulatory

Medicago Announces Positive Phase 1 Results For Its COVID-19 Vaccine Candidate

Published: 11/10/2020 11:32 GMT
Dynavax Technologies Corp (DVAX) - Medicago Announces Positive Phase 1 Results for Its Covid-19 Vaccine Candidate.
Medicago - There Were No Severe Adverse Events Reported in Study; Reactogenicity Events Were Generally Mild to Moderate & Short in Duration.
Medicago - Significant Humoral, Cell-mediated Immune Responses Observed With Gsk's Pandemic Adjuvant Technology and Dynavax’s Cpg 1018.
Medicago - Plans to Proceed With Phase 2/3 Clinical Trial for Covid-19 Vaccine Candidate, Subject to Regulatory Approval.
Medicago - Trial Results Showed 100% of Subjects Developed Promising Antibody Response After Two Doses of Covid-19 Adjuvanted Vaccine Candidate.
Medicago - Based on Overall Data Profile, 3.75 Mcg/dose With Gsk’s Pandemic Adjuvant Was Selected for Phase 2/3 Clinical Trial.
Medicago - All Subjects in Group With Gsk’s Pandemic Adjuvant Developed Anti-spike Igg Antibodies After Single Dose of Vaccine.